^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCND1 amplification

    i
    Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
    Entrez ID:
    595
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Palbociclib and Pembrolizumab in Central Nervous System Metastases (NCT02896335)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/02/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3
    |
    CCNE1 amplification • CCND1 amplification • CDK4 amplification
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib)
    A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (NCT03834740)
    Phase 1
    St. Joseph's Hospital and Medical Center, Phoenix
    Completed
    Last update posted :
    05/10/2024
    Initiation :
    12/21/2018
    Primary completion :
    02/18/2022
    Completion :
    02/18/2022
    PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B
    |
    PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression
    |
    everolimus • Kisqali (ribociclib)
    A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) (NCT04116541)
    Phase 2
    Centre Leon Berard
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/28/2020
    Primary completion :
    02/01/2026
    Completion :
    11/01/2026
    KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK
    |
    KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)
    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 (NCT03310879)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    11/21/2017
    Primary completion :
    12/31/2024
    Completion :
    04/30/2025
    CCND1 • CDK4 • CDK6
    |
    CCND1 amplification • CDK4 amplification • CCND1 mutation
    |
    Verzenio (abemaciclib)
    Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (NCT04439201)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    05/31/2016
    Primary completion :
    03/09/2021
    Completion :
    12/31/2025
    CCND1
    |
    CCND1 amplification
    |
    Ibrance (palbociclib)
    CDK4/6 Tumor, Abemaciclib, Paclitaxel (NCT04594005)
    Phase 1/2
    Yonsei University
    Active, not recruiting
    Last update posted :
    10/06/2023
    Initiation :
    02/25/2021
    Primary completion :
    08/10/2024
    Completion :
    08/10/2024
    CCND1 • CDK4 • CDK6
    |
    CCND1 amplification • CDK4 amplification • CCND1 mutation
    |
    paclitaxel • Verzenio (abemaciclib)
    Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) (NCT03356223)
    Phase 2
    Centre Leon Berard
    Completed
    Last update posted :
    02/23/2023
    Initiation :
    02/05/2018
    Primary completion :
    11/05/2022
    Completion :
    12/05/2022
    CDKN2A • CCND1
    |
    CDKN2A deletion • CCND1 amplification • CDK4 amplification
    |
    Erbitux (cetuximab) • Verzenio (abemaciclib)
    A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer (NCT03344536)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/24/2022
    Initiation :
    11/10/2017
    Primary completion :
    08/12/2021
    Completion :
    08/12/2021
    HER-2 • ER • PGR • FGFR • CCND1 • FGF3
    |
    HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification
    |
    fulvestrant • zoligratinib (Debio 1347)
    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790)
    Phase 2
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    03/11/2021
    Initiation :
    10/01/2009
    Primary completion :
    10/01/2019
    Completion :
    10/01/2019
    HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2
    |
    KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation
    |
    cisplatin • Ibrance (palbociclib)
    Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (NCT00721409)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    11/04/2019
    Initiation :
    09/15/2008
    Primary completion :
    11/29/2013
    Completion :
    12/20/2017
    HER-2 • ER • CDKN2A • CCND1
    |
    ER positive • HER-2 negative • CCND1 amplification • CCND1 expression • ER positive + HER-2 negative
    |
    Ibrance (palbociclib) • letrozole
    LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) (NCT02187783)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    07/18/2019
    Initiation :
    08/25/2014
    Primary completion :
    01/17/2018
    Completion :
    01/17/2018
    CDKN2A • CCND1 • CDK4 • CDK6 • CCND3
    |
    CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification
    |
    Kisqali (ribociclib)